Laddar...
Imatinib mesylate and nilotinib decrease synthesis of bone matrix in vitro
Tyrosine kinase inhibitors (TKIs), such as imatinib (IMA) and nilotinib (NIL), are the cornerstone of chronic myeloid leukemia (CML) treatment via the blockade of the oncogenic BCR-ABL1 fusion protein. However, skeletal side effects are commonly observed in pediatric patients receiving long-term tre...
Sparad:
| I publikationen: | Oncol Lett |
|---|---|
| Huvudupphovsmän: | , , , , , , , |
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
D.A. Spandidos
2019
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6614669/ https://ncbi.nlm.nih.gov/pubmed/31423283 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/ol.2019.10518 |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|